RxDoctor Payments DataLook up a doctor →

Steven Marso

Interventional Cardiology · Kansas City, MONPI 1528026374

Payments from drug & device makers

$920,746in general payments, 2019–2025

Across 900 payments — averaging $1023.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk AS$686K
  • Novartis$131K
  • Boston Scientific$77K
  • Asahi Intecc CO., LTD.$9K
  • Asahi Intecc USA, Inc.$7K
  • Siemens Medical Solutions USA, Inc.$7K
  • plus $3K from 19 others
$5,250in research payments, 2019–2025

Across 2 payments — averaging $2625.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novo Nordisk AS$5K

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$920,746 in reported general payments places this provider in the 90th percentile of 182 interventional cardiology providers in Missouri.

See all interventional cardiology providers in Missouri

Other interventional cardiology in Kansas City

See the full list for Missouri

Where these figures come from

Is this you, or does something look wrong? →